MCID: MSC033
MIFTS: 52

Muscle Disorders

Categories: Neuronal diseases, Muscle diseases, Genetic diseases

Aliases & Classifications for Muscle Disorders

Summaries for Muscle Disorders

MedlinePlus : 41 your muscles help you move and help your body work. different types of muscles have different jobs. there are many problems that can affect muscles. muscle disorders can cause weakness, pain or even paralysis. causes of muscle disorders include injury or overuse, such as sprains or strains, cramps or tendinitis a genetic disorder, such as muscular dystrophy some cancers inflammation, such as myositis diseases of nerves that affect muscles infections certain medicines sometimes the cause is not known.

MalaCards based summary : Muscle Disorders, also known as myopathy, is related to myofibrillar myopathy and central nervous system angiosarcoma, and has symptoms including back pain, leg cramps and muscle cramp. An important gene associated with Muscle Disorders is CLCN1 (Chloride Voltage-Gated Channel 1), and among its related pathways/superpathways are Cardiac conduction and ECM-receptor interaction. The drugs Benzocaine and Entecavir have been mentioned in the context of this disorder. Affiliated tissues include Placenta, heart and brain, and related phenotype is muscle.

Related Diseases for Muscle Disorders

Diseases in the Muscle Disorders family:

Ano5-Related Muscle Diseases Chkb-Related Muscle Diseases
Col12a1-Related Muscle Diseases Fkrp-Related Muscle Diseases
Fktn-Related Muscle Diseases Gtdc2-Related Muscle Diseases
Ispd-Related Muscle Diseases Large1-Related Muscle Diseases
Lmna-Related Muscle Diseases Pomgnt1-Related Muscle Diseases
Pomt1-Related Muscle Diseases Pomt2-Related Muscle Diseases
Dag1-Related Muscle Diseases

Diseases related to Muscle Disorders via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
id Related Disease Score Top Affiliating Genes
1 myofibrillar myopathy 10.6 RYR1 SELENON
2 central nervous system angiosarcoma 10.4 CLCN1 MIR206 RYR1
3 uterine corpus endometrial stromal sarcoma 10.4 RYR1 SELENON TPM3
4 myopathy, congenital, with fiber-type disproportion 10.4 RYR1 SELENON TPM3
5 congenital myopathy 10.4
6 myotonia congenita, recessive 10.4
7 myopathy, x-linked, with excessive autophagy 10.4
8 myotonia congenita, dominant 10.4
9 myopathy, vacuolar, with casq1 aggregates 10.4
10 miyoshi muscular dystrophy 1 10.4
11 microcephaly and chorioretinopathy 1 10.3 RYR1 SELENON TPM3
12 ulnar hemimelia, unilateral 10.3 RYR2 TTN
13 ulnar hemimelia, bilateral 10.3 RYR2 TTN
14 muscular dystrophy, rigid spine, 1 10.3 COL6A2 SELENON TTN
15 tibial hemimelia, bilateral 10.3 RYR2 TTN
16 muscular dystrophy, limb-girdle, type 2w 10.2
17 myopathy, distal, 5 10.2
18 left ventricular noncompaction 10.2
19 salih myopathy 10.2
20 nemaline myopathy 6, autosomal dominant 10.2
21 reducing body myopathy 10.2
22 nemaline myopathy 9 10.2
23 myopathy, centronuclear, 4 10.2
24 centronuclear myopathy 5 10.2
25 congenital fiber-type disproportion 10.2
26 centronuclear myopathy, autosomal, modifier of 10.2
27 proximal myopathy and ophthalmoplegia 10.2
28 nemaline myopathy 8, autosomal recessive 10.2
29 myopathy, myofibrillar, 7 10.2
30 malignant hyperthermia susceptibility 1 10.2
31 muscular dystrophy, limb-girdle, type 2x 10.2
32 central core disease 10.2
33 myopathy, centronuclear, autosomal recessive 10.2
34 nemaline myopathy 4, autosomal dominant 10.2
35 myotubular myopathy, x-linked 10.2
36 neutral lipid storage disease with myopathy 10.2
37 fingerprint body myopathy 10.2
38 normokalemic periodic paralysis 10.2
39 nemaline myopathy 1, autosomal dominant or recessive 10.2
40 stormorken syndrome 10.2
41 foot drop 10.2
42 thyrotoxic periodic paralysis 1 10.2
43 myopathy, centronuclear, 3 10.2
44 myopathy, scapulohumeroperoneal 10.2
45 muscular dystrophy, limb-girdle, type 2c 10.2
46 multifocal motor neuropathy 10.2
47 laing distal myopathy 10.2
48 arrhythmogenic right ventricular dysplasia 2 10.2 RYR1 RYR2
49 monocular esotropia 10.2 CLCN1 RYR1
50 cylindrical spirals myopathy 10.2 COL6A3 RYR1 SELENON

Graphical network of the top 20 diseases related to Muscle Disorders:



Diseases related to Muscle Disorders

Symptoms & Phenotypes for Muscle Disorders

UMLS symptoms related to Muscle Disorders:


back pain, leg cramps, muscle cramp, muscle rigidity, muscle spasticity, myoclonus, sciatica, torticollis, muscle weakness, spasmodic torticollis, musculoskeletal symptom, myalgia, joint symptom

MGI Mouse Phenotypes related to Muscle Disorders:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.28 CAV3 CLCN1 COL6A1 COL6A3 RYR1 RYR2

Drugs & Therapeutics for Muscle Disorders

Drugs for Muscle Disorders (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1144)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
2
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
3
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 50-24-8 5755
6
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 1 202409-33-4 123619
7
Milnacipran Approved Phase 4,Phase 2,Phase 3,Phase 1 92623-85-3 65833
8
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
9
Ramipril Approved Phase 4 87333-19-5 5362129
10
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1 50-48-6 2160
11
Cyclobenzaprine Approved Phase 4,Phase 3,Phase 2 303-53-7 2895
12
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
13
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 60142-96-3 3446
14
Perphenazine Approved Phase 4,Phase 2,Phase 3,Phase 1 58-39-9 4748
15
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-84-3 187
16
Sodium oxybate Approved Phase 4,Phase 3,Phase 2 502-85-2 5360545
17
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
18
Dinoprostone Approved Phase 4 363-24-6 5280360
19
Rocuronium Approved Phase 4,Phase 3,Phase 2,Phase 1 119302-91-9, 143558-00-3 441290
20
Succinylcholine Approved Phase 4,Phase 3,Phase 2 306-40-1 5314
21
Donepezil Approved Phase 4,Phase 3 120014-06-4 3152
22
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 1,Phase 2 128-13-2 31401
23
Moxonidine Approved Phase 4 75438-57-2 4810
24
Ranolazine Approved, Investigational Phase 4,Phase 2 142387-99-3, 95635-55-5 56959
25
Magnesium oxide Approved Phase 4 1309-48-4 14792
26
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
27
Eptifibatide Approved, Investigational Phase 4 188627-80-7 123610
28
Thrombin Approved Phase 4
29
Letrozole Approved, Investigational Phase 4,Phase 2 112809-51-5 3902
30
Riluzole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1744-22-5 5070
31
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
32
Levodopa Approved Phase 4,Phase 2,Early Phase 1 59-92-7 6047
33
Paclitaxel Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 33069-62-4 36314
34 Trapidil Approved Phase 4 15421-84-8
35
Diazepam Approved, Illicit, Vet_approved Phase 4 439-14-5 3016
36
Bezafibrate Approved Phase 4,Phase 3,Phase 2 41859-67-0 39042
37
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 137-58-6 3676
38
Polidocanol Approved Phase 4,Phase 2 9002-92-0
39
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
40
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 148553-50-8 5486971
41
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260
42
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 103-90-2 1983
43
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2 27203-92-5 33741
44
Naproxen Approved, Vet_approved Phase 4,Phase 1 22204-53-1 1302 156391
45
Mivacurium Approved Phase 4,Phase 2 106791-40-6, 133814-19-4 5281042
46
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 1 525-66-6 4946
47
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1 15687-27-1 3672
48
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 2078-54-8 4943
49
Remifentanil Approved Phase 4,Phase 3,Phase 2 132875-61-7 60815
50
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1 1134-47-0 2284

Interventional clinical trials:

(show top 50) (show all 5616)

id Name Status NCT ID Phase Drugs
1 Identification of Carnitine-Responsive Cardiomyopathy Unknown status NCT01904396 Phase 4 Carnitine
2 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
3 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
4 6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
5 A Randomized Trial to Evaluate the Effectiveness of Transferring the Flexor Hallucis Longus Tendon Unknown status NCT01341509 Phase 4
6 Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia Unknown status NCT00755521 Phase 4 etoricoxib
7 Study of Fibromyalgia Treated With Milnacipran Unknown status NCT01125423 Phase 4 Milnacipran
8 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
9 The Study of Using Esophageal Pressure to Guide the PEEP Setting in Abdominal Hypertension Patients Who Undergoing Mechanical Ventilation Unknown status NCT01825304 Phase 4
10 Ramipril Versus Carvedilol in Duchenne and Becker Patients Unknown status NCT00819845 Phase 4 carvedilol;ramipril
11 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
12 The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy Unknown status NCT00606775 Phase 4 Carvedilol
13 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
14 Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease Unknown status NCT01901224 Phase 4 Metformin 1000 mg;Placebo
15 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
16 Aliskiren and Muscle Sympathetic Nerve Activity Unknown status NCT00719316 Phase 4 Aliskiren
17 Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain Unknown status NCT02339662 Phase 4 Gabapentin;Amitriptyline
18 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
19 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4 Human papilloma virus vaccine (cervarix)
20 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
21 Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis Unknown status NCT00173706 Phase 4 L-Carnitine Injection
22 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
23 The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
24 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Unknown status NCT01256021 Phase 4 Botulinum Toxin Type A
25 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
26 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
27 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
28 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
29 Comparison of Surgical Conditions in Cesarean Section Under General Anesthesia With Deep Neuromuscular Blockade Versus Succinylcholine Unknown status NCT01941628 Phase 4 Rocuronium;Succinylcholine
30 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
31 The Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4 Donepezil
32 CPAP for Infantile Pompe Disease Unknown status NCT02405624 Phase 4
33 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4 Intravesical injection of Botulinum A toxin
34 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4 Botox;Saline Solution
35 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
36 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
37 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
38 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
39 Influence of Profound Muscle Relaxation on Muscle Trauma and Postoperative Pulmonary Function Unknown status NCT01804933 Phase 4 profound neuromuscular blockade
40 Effect of Ranolazine on Valvular Disease in Patients With Pacemakers Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
41 Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism Unknown status NCT01336439 Phase 4 Botulinum toxin type A (Meditoxin®)
42 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
43 Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin Unknown status NCT00370045 Phase 4 Bivalirudin with and without eptifibatide
44 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4 Letrozole
45 Inspiratory Muscle Training in Patients With Autonomic Neuropathic Unknown status NCT00752440 Phase 4
46 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Unknown status NCT00560287 Phase 4
47 Inspiratory Muscle Training in Patients With End Stage Renal Failure Unknown status NCT01347775 Phase 4
48 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
49 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
50 Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide™ Stent Versus Taxus™ Unknown status NCT00914420 Phase 4

Search NIH Clinical Center for Muscle Disorders

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Muscle Disorders cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Muscle Disorders:
PLX-PAD, placental-derived mesenchymal-like stromal cells for muscle disorders
Embryonic/Adult Cultured Cells Related to Muscle Disorders:
Placenta-derived adherent stromal cell (PLX) PMIDs: 18154467 19478280

Genetic Tests for Muscle Disorders

Anatomical Context for Muscle Disorders

MalaCards organs/tissues related to Muscle Disorders:

39
Heart, Brain, Skeletal Muscle, Testes, Kidney, Bone, Lung
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Muscle Disorders:
id Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate

Publications for Muscle Disorders

Articles related to Muscle Disorders:

(show top 50) (show all 60)
id Title Authors Year
1
Muscle disorders: FGF19 reduces muscle wasting. ( 28729723 )
2017
2
Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders. ( 28434044 )
2017
3
The potential of obscurin as a therapeutic target in muscle disorders. ( 28756711 )
2017
4
Immunohistochemical analysis of canine and feline muscle disorders using formalin-fixed, paraffin-embedded tissues. ( 28599613 )
2017
5
Muscle disorders: Preventing diaphragm dysfunction. ( 27681795 )
2016
6
Novel treatment strategies for smooth muscle disorders: Targeting Kv7 potassium channels. ( 27179745 )
2016
7
The influence of psychological flexibility on life satisfaction and mood in muscle disorders. ( 27196863 )
2016
8
Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders. ( 27037223 )
2016
9
Skeletal muscle disorders of glycogenolysis and glycolysis. ( 27231184 )
2016
10
Targeted massively parallel sequencing and histological assessment of skeletal muscles for the molecular diagnosis of inherited muscle disorders. ( 27600705 )
2016
11
Next-generation sequencing approaches for the diagnosis of skeletal muscle disorders. ( 27454578 )
2016
12
Deficiency Of I+-actinin-3 Is Associated With Increased Incidence Of On Indirect Muscle Disorders/Injuries In Elite Football Players.: 2617 Board #140 June 3, 9: 30 AM - 11: 00 AM. ( 27361253 )
2016
13
Genetic muscle disorders study. ( 27039558 )
2016
14
Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing. ( 26809617 )
2016
15
Common Creatine Kinase gene mutation results in falsely reassuring CK levels in muscle disorders. ( 26568611 )
2015
16
203rd ENMC international workshop: Respiratory pathophysiology in congenital muscle disorders: Implications for pro-active care and clinical research 13-15 December, 2013, Naarden, The Netherlands. ( 25613806 )
2015
17
Muscle disorders: Combating cachexia in cancer. ( 26471368 )
2015
18
Taurine: the appeal of a safe amino acid for skeletal muscle disorders. ( 26208967 )
2015
19
Influence of the MCT1 rs1049434 on Indirect Muscle Disorders/Injuries in Elite Football Players. ( 26478856 )
2015
20
Regulating PPARI' Signaling as a Potential Therapeutic Strategy for Skeletal Muscle Disorders in Heart Failure. ( 25770240 )
2015
21
Skeletal muscle perfusion and stem cell delivery in muscle disorders using intra-femoral artery canulation in mice. ( 26341268 )
2015
22
Congenital muscular dystrophies: New evidence-based guidelines for the diagnosis and management of this evolving group of muscle disorders. ( 25900129 )
2015
23
Editorial: Stem Cell-Based and Gene Therapy for Hereditary Muscle Disorders. ( 26206328 )
2015
24
Incidence of skeletal muscle disorders after statins' treatment: consequences in clinical and EMG picture. ( 24878976 )
2014
25
The Genetics of Skeletal Muscle Disorders in Horses. ( 25387114 )
2014
26
K(V)7 potassium channels: a new therapeutic target in smooth muscle disorders. ( 24333708 )
2014
27
Issues & Opinions - The potential of psychological interventions to improve quality of life and mood in muscle disorders. ( 25297932 )
2014
28
Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary alterations in mitochondrial calcium signaling. ( 24336167 )
2014
29
Human skeletal muscle xenograft as a new preclinical model for muscle disorders. ( 24452336 )
2014
30
Reining in nuclear factor-kappaB in skeletal muscle disorders. ( 23493016 )
2013
31
Proteomic identification of biomarkers of skeletal muscle disorders. ( 23387498 )
2013
32
Quetiapine and cardiac muscle disorders. ( 23951594 )
2013
33
Muscle disorders: the latest investigations. ( 24004391 )
2013
34
One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders. ( 22880633 )
2013
35
Creatine for treating muscle disorders. ( 23740606 )
2013
36
Nemaline myopathy in a newborn infant: a rare muscle disorder. ( 24166571 )
2013
37
Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases. ( 22065858 )
2012
38
Stem cell therapies for muscle disorders. ( 22918488 )
2012
39
Masticatory muscle disorders diagnostic criteria: the American Academy of Orofacial Pain versus the research diagnostic criteria/temporomandibular disorders (RDC/TMD). ( 22882635 )
2012
40
Creatine for treating muscle disorders. ( 21328269 )
2011
41
Growing muscle has different sarcolemmal properties from adult muscle: a proposal with scientific and clinical implications: reasons to reassess skeletal muscle molecular dynamics, cellular responses and suitability of experimental models of muscle disorders. ( 21500235 )
2011
42
Delay in diagnosis of muscle disorders depends on the subspecialty of the initially consulted physician. ( 21542919 )
2011
43
Genetic variability of transcript abundance in pig peri-mortem skeletal muscle: eQTL localized genes involved in stress response, cell death, muscle disorders and metabolism. ( 22053791 )
2011
44
Caveolinopathies: translational implications of caveolin-3 in skeletal and cardiac muscle disorders. ( 21496630 )
2011
45
An internet-based system for home monitoring of respiratory muscle disorders. ( 21096291 )
2010
46
Eosinophilia-associated muscle disorders: an immunohistological study with tissue localisation of major basic protein in distinct clinicopathological forms. ( 19139036 )
2009
47
Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm. ( 18313359 )
2008
48
A psychological study on patients with masticatory muscle disorder and sleep bruxism. ( 16933460 )
2006
49
Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels. ( 16075044 )
2005
50
Collagen VI related muscle disorders. ( 16141002 )
2005

Variations for Muscle Disorders

Expression for Muscle Disorders

Search GEO for disease gene expression data for Muscle Disorders.

GO Terms for Muscle Disorders

Cellular components related to Muscle Disorders according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.77 CAV3 COL6A1 COL6A2 RYR1 RYR2
2 extracellular exosome GO:0070062 9.65 COL6A1 COL6A2 COL6A3 ENO3 PIK3C2A PRG2
3 Z disc GO:0030018 9.58 CAV3 RYR2 TTN
4 collagen trimer GO:0005581 9.5 COL6A1 COL6A2 COL6A3
5 smooth endoplasmic reticulum GO:0005790 9.46 RYR1 RYR2
6 I band GO:0031674 9.43 RYR1 TTN
7 junctional sarcoplasmic reticulum membrane GO:0014701 9.26 RYR1 RYR2
8 collagen type VI trimer GO:0005589 9.16 COL6A1 COL6A3
9 sarcolemma GO:0042383 9.02 CAV3 CLCN1 COL6A1 COL6A2 COL6A3

Biological processes related to Muscle Disorders according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 regulation of heart rate GO:0002027 9.52 CAV3 RYR2
2 skeletal muscle fiber development GO:0048741 9.51 RYR1 SELENON
3 regulation of cardiac muscle contraction GO:0055117 9.49 CAV3 RYR2
4 ventricular cardiac muscle cell action potential GO:0086005 9.46 CAV3 RYR2
5 protein heterotrimerization GO:0070208 9.43 COL6A1 COL6A2
6 collagen catabolic process GO:0030574 9.43 COL6A1 COL6A2 COL6A3
7 cardiac muscle hypertrophy GO:0003300 9.4 RYR2 TTN
8 response to caffeine GO:0031000 9.37 RYR1 RYR2
9 cellular response to caffeine GO:0071313 9.32 RYR1 RYR2
10 positive regulation of myotube differentiation GO:0010831 9.18 CAV3
11 release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0014808 9.16 RYR1 RYR2
12 muscle contraction GO:0006936 9.02 CAV3 CLCN1 RYR1 TPM3 TTN
13 detection of muscle stretch GO:0035995 8.96 CAV3 TTN

Molecular functions related to Muscle Disorders according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.56 CAV3 RYR1 RYR2 TTN
2 calcium-release channel activity GO:0015278 9.16 RYR1 RYR2
3 calcium-induced calcium release activity GO:0048763 8.96 RYR1 RYR2
4 ryanodine-sensitive calcium-release channel activity GO:0005219 8.62 RYR1 RYR2

Sources for Muscle Disorders

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....